T2 Organism 2080 2088 patients
T3 Condition 477 484 patient
T5 Intervention 2475 2504 treatment-refractory patients
T6 Organism 1683 1691 patients
T7 Intervention 287 296  patients
T8 Organism 2417 2438 trastuzumab and lapat
T11 Condition 968 975 patient
T12 Organism 259 280 trastuzumab and lapat
T13 Organism 1601 1609 patients
T14 Condition 106 112 tumour
T16 Condition 491 500 KRAS exon
T17 Condition 1560 1570 colorectal
T18 Organism 2496 2504 patients
T19 Condition 1938 1945 patient
T20 Level 236 246 antitumour
T21 Intervention 2196 2205  patients
T22 Condition 1683 1690 patient
T23 Condition 302 306 HER2
T24 Condition 1615 1619 HER2
T25 Intervention 986 1009 intravenous trastuzumab
T26 Condition 763 767 HER2
T27 Condition 153 157 HER2
T28 Condition 550 578 metastatic colorectal cancer
T29 Organism 2440 2443 ib 
T30 Condition 2125 2132 patient
T31 Condition 316 326 colorectal
T32 Condition 1494 1501 patient
T34 Condition 2496 2503 patient
T35 Condition 521 578  wild-type and HER2-positive metastatic colorectal cancer
T36 Condition 302 333 HER2-positive colorectal cancer
T37 Condition 2197 2204 patient
T38 Organism 1085 1088 ib 
T39 Intervention 476 485  patients
T40 Intervention 1188 1197  patients
T43 Condition 561 571 colorectal
T45 Condition 536 578 HER2-positive metastatic colorectal cancer
T47 Condition 40 44 HER2
T50 Gene 1788 1794 Oct 15
T51 Condition 240 246 tumour
T52 Condition 1884 1891 patient
T53 Condition 179 189 colorectal
T54 Condition 2524 2552 metastatic colorectal cancer
T55 Condition 536 540 HER2
T57 Condition 288 295 patient
T58 Disease 2181 2188 fatigue
T59 Condition 2535 2545 colorectal
T60 Condition 123 130 patient
T61 Biomarker 2247 2256 bilirubin
T62 Organism 1494 1502 patients
T63 Condition 491 503 KRAS exon 2 
T64 Condition 2224 2231 patient
T65 Condition 911 921 colorectal
T66 Intervention 1883 1892  patients
T67 Condition 1549 1577 metastatic colorectal cancer
T68 Intervention 2079 2088  patients
T69 Condition 2510 2552 HER2-positive metastatic colorectal cancer
T71 Condition 2510 2514 HER2
T72 Intervention 967 976  patients
T73 Biomarker 1073 1087 oral lapatinib
T74 Organism 82 85 ib 
T75 Condition 434 449 academic cancer
T76 Biomarker 2433 2442 lapatinib
T77 Condition 2080 2087 patient
T80 Biomarker 1078 1087 lapatinib
T81 Intervention 1682 1691  patients
T83 Organism 2125 2133 patients
T84 Protein 2348 2360 drug-related
T85 Condition 782 796 tumour samples
T87 Intervention 2495 2504  patients
T88 Condition 1629 1635 tumour
T89 Condition 1508 1517 KRAS exon
T90 Condition 1508 1520 KRAS exon 2 
T91 Biomarker 75 84 lapatinib
T93 Disease 2207 2216 skin rash
T94 Intervention 2124 2133  patients
